EVEROLIMUS is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Biocon Pharma Inc.. The primary component is Everolimus.
| Product ID | 70377-010_0e7fa07d-c388-8756-6d9e-75590a5f44cf |
| NDC | 70377-010 |
| Product Type | Human Prescription Drug |
| Proprietary Name | EVEROLIMUS |
| Generic Name | Everolimus |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2021-10-01 |
| Marketing Category | ANDA / |
| Application Number | ANDA214182 |
| Labeler Name | Biocon Pharma Inc. |
| Substance Name | EVEROLIMUS |
| Active Ingredient Strength | 3 mg/1 |
| Pharm Classes | Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2021-10-01 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0054-0470 | Everolimus | Everolimus |
| 0054-0471 | Everolimus | Everolimus |
| 0054-0472 | Everolimus | Everolimus |
| 0054-0480 | Everolimus | Everolimus |
| 0054-0481 | Everolimus | Everolimus |
| 0054-0482 | Everolimus | Everolimus |
| 0054-0497 | Everolimus | Everolimus |
| 0054-0604 | Everolimus | Everolimus |
| 49884-119 | Everolimus | Everolimus |
| 49884-127 | Everolimus | Everolimus |
| 49884-125 | Everolimus | Everolimus |
| 0378-3098 | everolimus | everolimus |
| 0093-7766 | Everolimus | Everolimus |
| 0378-3097 | everolimus | everolimus |
| 0093-7767 | Everolimus | Everolimus |
| 0093-7768 | Everolimus | Everolimus |
| 0378-3096 | everolimus | everolimus |
| 0078-0414 | Zortress | everolimus |
| 0078-0415 | Zortress | everolimus |
| 0078-0417 | Zortress | everolimus |
| 0078-0422 | Zortress | everolimus |